<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bevacizumab is a humanized monoclonal antibody to VEGF-A, an important therapeutic target through its proangiogenic effects on a variety of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Bevacizumab has demonstrated clinically meaningful benefit in conjunction with chemotherapy for patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> as well as other <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types </plain></SENT>
<SENT sid="2" pm="."><plain>Bevacizumab is a well-tolerated therapy with regard to toxicity, in keeping with its biological vascular effect </plain></SENT>
<SENT sid="3" pm="."><plain>In this era of personalized medicine, current Phase II and III trials are further defining its role at various stages of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> and the optimal sequencing with cytotoxic and other targeted agents to achieve further improvements in patient outcome </plain></SENT>
<SENT sid="4" pm="."><plain>Translational research for biomarker discovery and validation and further study into mechanisms of resistance are essential for future development and sustained benefit with this class of therapeutic agents </plain></SENT>
</text></document>